<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01012544</url>
  </required_header>
  <id_info>
    <org_study_id>MAPCAT01</org_study_id>
    <nct_id>NCT01012544</nct_id>
  </id_info>
  <brief_title>Platelet Reactivity in Stent Thrombosis Patients</brief_title>
  <acronym>MAPCAT</acronym>
  <official_title>The MAgnitude of Platelet Inhibition and the Pharmacokinetics of a 600 mg Loading Dose of Clopidogrel, in Different Patient CATegories (Stable Angina Versus Acute-coronary Syndromes Versus ST-elevated Myocardial Infarction).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Antonius Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies have demonstrated a marked interindividual variability of clopidogrel's
      capacity to inhibit platelet aggregation with a substantial proportion (11-34%) of the
      patients considered non-responders to clopidogrel treatment. Variable intestinal absorption
      is suggested to contribute to the inconsistencies in response to clopidogrel. However, little
      is known about intestinal absorption in subjects who had suffered from a stent thrombosis.
      The MAPCAT-study has been designed to investigate whether plasma pharmacokinetics
      (represented by Cmax, Tmax and the AUC) after a 600 mg loading dose are significantly
      different between subjects who have suffered a stent thrombosis and subjects who have not
      suffered a stent thrombosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:

      The first objective of the MAPCAT-study is to investigate whether plasma pharmacokinetics
      (Cmax, Tmax and AUC) of an additional 600 mg loading dose are impaired in patients with a
      history of stent thrombosis.

      The second objective of the MAPCAT study is to investigate whether genetic polymorphisms in
      receptors, enzymes and ligands involved in the process of thrombosis and haemostasis as well
      in the conversion-process of clopidogrel into its metabolites do have influence on both the
      absolute magnitude of platelet inhibition and Cmax, Tmax and AUC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentrations of unchanged clopidogrel, its active thiol metabolite and its inactive carboxyl metabolite between the different patient groups after the administration of a 600 mg loading dose of clopidogrel.</measure>
    <time_frame>6 hours after the administration of a 600mg loading dose of clopidogrel</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The magnitude of platelet reactivity as measured with several commercial available platelet function tests before and 6 hours after the ingestion of the loading dose.</measure>
    <time_frame>platelet reactivity measured at baseline and 6 hours after a 600 mg clopidogrel loading dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory Endpoint: prevalence of various genetic polymorphisms that might influence the pharmacokinetics of clopidogrel</measure>
    <time_frame>blood obtained for genetic sampeling at timepoint of first study blood collection</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">187</enrollment>
  <condition>Coronary Artery Stent Thrombosis</condition>
  <arm_group>
    <arm_group_label>stent thrombosis patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with a history of a stent thrombosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without a history of a stent thrombosis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients without a history of stent thrombosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>both arms of the study (patients with a history of stent thrombosis as well as patients who did not suffer from a stent thrombosis) will be given a 600 mg loading dose of clopidogrel</description>
    <arm_group_label>stent thrombosis patients</arm_group_label>
    <arm_group_label>Patients without a history of a stent thrombosis</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a history of a stent thrombosis in the period 2004-2008.

        Exclusion Criteria:

          -  Persistent acute ST-segment elevation

          -  Successful revascularization during the qualifying hospitalization, prior to study
             entry

          -  Acute pulmonary edema, hypotension, or evidence of cardiogenic shock

          -  Clinically significant liver disease

          -  End stage kidney disease requiring dialysis

          -  Use at study entry of drugs that are strong inhibitors of cytochrome P450 3A4 and
             CYP3A5 (i.e. clarithromycin, erythromycin, itraconazole, ketoconazole)

          -  Contraindications to antithrombotic/antiplatelet therapy

          -  Failed coronary intervention in the previous 2 weeks

          -  Malignancies

          -  Increased risk of bleeding (previous stroke in the past months, active bleeding or
             bleeding diathesis, recent trauma or major surgery in the last month, suspected aortic
             dissection, oral anticoagulation therapy with coumarin derivate within 7 days, recent
             use of GPIIb/IIIa inhibitors within 14 days, severe uncontrolled hypertension &gt;180
             mmHg unresponsive to therapy)

          -  Relevant hematologic deviations (haemoglobin &lt;100g/L (6,2 mmol/L) or hematocrit &lt;34%,
             platelet count &lt;100 x 109 /L or platelet count &gt; 600 x 109/L)

          -  Known allergy to clopidogrel

          -  Pregnancy (present or suspected)

          -  uncontrolled hypertension at time of randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J.M. ten Berg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Antonius center for platelet function research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <zip>3435CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Elsenberg EH, van Werkum JW, van de Wal RM, Zomer AC, Bouman HJ, Verheugt FW, Berg JM, Hackeng CM. The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests. Thromb Haemost. 2009 Oct;102(4):719-27. doi: 10.1160/TH09-05-0285.</citation>
    <PMID>19806258</PMID>
  </reference>
  <reference>
    <citation>Taubert D, Bouman HJ, van Werkum JW. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009 May 21;360(21):2249-50; author reply 2251. doi: 10.1056/NEJMc090391.</citation>
    <PMID>19458375</PMID>
  </reference>
  <reference>
    <citation>van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ, Koolen JJ, Brueren BR, Dambrink JH, Hautvast RW, Verheugt FW, ten Berg JM. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol. 2009 Apr 21;53(16):1399-409. doi: 10.1016/j.jacc.2008.12.055.</citation>
    <PMID>19371823</PMID>
  </reference>
  <reference>
    <citation>Heestermans AA, van Werkum JW, Schömig E, ten Berg JM, Taubert D. Clopidogrel resistance caused by a failure to metabolize clopidogrel into its metabolites. J Thromb Haemost. 2006 May;4(5):1143-5.</citation>
    <PMID>16689772</PMID>
  </reference>
  <reference>
    <citation>Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, Kastrati A, Schömig A, Schömig E. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006 Nov;80(5):486-501.</citation>
    <PMID>17112805</PMID>
  </reference>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2009</study_first_submitted>
  <study_first_submitted_qc>November 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2009</study_first_posted>
  <last_update_submitted>August 22, 2011</last_update_submitted>
  <last_update_submitted_qc>August 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Antonius Hospital</investigator_affiliation>
    <investigator_full_name>J.M. ten Berg</investigator_full_name>
    <investigator_title>Cardiologist, MD, PhD, FESC, FACC</investigator_title>
  </responsible_party>
  <keyword>clopidogrel</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>platelet function tests</keyword>
  <keyword>platelet reactivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

